Mitaclau (Desmopressin)

Desmopressin mimics the natural hormone vasopressin and selectively activates V2 receptors in the kidney collecting ducts. This triggers a cascade that inserts aquaporin‑2 channels into the cell membrane, allowing more water to be reabsorbed. The same receptor activation also promotes release of clotting factors from endothelial cells, aiding hemostasis.

The dose of Mitaclau is individualized by the prescribing clinician based on the specific indication, patient age, weight, renal function and response to therapy. Physicians determine the appropriate amount and frequency, and patients should follow the prescribed regimen without alteration.

Safety data for desmopressin in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Healthcare providers weigh potential benefits against possible risks before prescribing to pregnant or nursing women, and close monitoring is advised if use is deemed necessary.

To request Mitaclau, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and assistance with import documentation.

Mitaclau (desmopressin) is a synthetic vasopressin analog with high selectivity for V2 receptors, offering a longer duration of action and fewer vasoconstrictive effects than natural vasopressin. Compared with other antidiuretic drugs, it provides reliable control of urine output and also has the unique benefit of raising clotting factor levels, making it useful for bleeding disorders.

Store Mitaclau at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight. Ensure the container is tightly closed to maintain stability, and discard any tablets that appear damaged or discolored.

Mitaclau is administered sublingually. The tablet is placed under the tongue and allowed to dissolve completely without chewing or swallowing whole. Patients should avoid eating or drinking for a few minutes after administration to ensure optimal absorption.

The most critical safety concerns involve severe hyponatremia and water intoxication, which can lead to seizures, cerebral edema, or coma. Patients must be monitored for rapid drops in serum sodium, especially when fluid intake is excessive or when interacting drugs increase the antidiuretic effect.

Mitaclau is contraindicated in individuals with known hypersensitivity to desmopressin or any formulation excipients, in patients with uncontrolled hyponatremia, and in those with severe renal impairment where water clearance is markedly reduced. Caution is also advised for patients with a history of thromboembolic events.